NanoViricidesNNVC
NNVC
About: Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Employees: 7
0
Funds holding %
of 6,815 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
113% more call options, than puts
Call options by funds: $49K | Put options by funds: $23K
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
0.07% less ownership
Funds ownership: 11.41% [Q2] → 11.34% (-0.07%) [Q3]
9% less funds holding
Funds holding: 34 [Q2] → 31 (-3) [Q3]
13% less capital invested
Capital invested by funds: $2.32M [Q2] → $2.01M (-$308K) [Q3]
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Research analyst outlook
We haven’t received any recent analyst ratings for NNVC.
Financial journalist opinion
Based on 6 articles about NNVC published over the past 30 days
Neutral
Accesswire
1 day ago
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is presenting at Biotech Showcase™ 2025 in San Fransisco, being held in parallel to the JP Morgan Life Sciences Conference. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco Day & Date Tuesday, January 14, 2025 Time, Track & Room 2:30pm PT, Yosemite A (Ballroom Level) Location Hilton San Fransisco - Union Square Anil R.
Positive
Proactive Investors
3 days ago
NanoViricides CEO discusses NV-387's broad spectrum promise - ICYMI
NanoViricides (NYSE-A:NNVC) CEO Dr Anil Diwan joined Proactive to highlight the company's lead drug candidate NV-387, which is targeting multiple viral families by mimicking receptors essential for viral infections. He highlighted that NV-387 has shown exceptional efficacy in preclinical studies, including curing RSV infections in animal models.
Positive
Proactive Investors
6 days ago
NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats
NanoViricides (NYSE-A:NNVC) has highlighted the growing need for innovative antiviral solutions amid rising concerns over multiple viral threats, including H5N1 bird flu, COVID-19, RSV, and human metapneumovirus (hMPV). The company is advancing NV-387, a promising broad-spectrum antiviral candidate designed to target a wide range of rapidly mutating RNA viruses.
Neutral
Accesswire
6 days ago
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals
SHELTON, CT / ACCESSWIRE / January 8, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), comments on the many viruses that could cause pandemics that are going around already. This season, two different genotypes of H5N1 bird flu, namely (a) the severe and lethal form D1.1 that has spread globally in birds, and (b) the less severe B3.13 genotype widely spread in diary cattle in North America are causing major concerns even as Seasonal Influenza cases abound.
Positive
Proactive Investors
3 weeks ago
NanoViricides sees NV-387 as a key defense against bird flu pandemic
NanoViricides (NYSE-A:NNVC) said it believes that its broad-spectrum antiviral candidate, NV-387, could be a critical tool in combating a potential bird flu pandemic caused by the H5N1 Influenza A virus. In a statement, the company claims the virus would be unable to evade NV-387, even as it mutates.
Neutral
Accesswire
3 weeks ago
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug. "Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R.
Neutral
Proactive Investors
1 month ago
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America
The rise of unexplained human cases of bird flu in North America means there is an urgent need for effective treatments that can withstand viral mutations. In this opinion article, Anil Diwan, CEO of NanoViricides (NYSE-A:NNVC), a clinical-stage nano-biopharmaceutical company that develops and commercializes drugs designed to treat viral infections, raises alarm over the evolving threat of H5N1 bird flu, highlighting recent research that shows the virus is just one mutation away from effectively targeting human cells.
Positive
Proactive Investors
1 month ago
NanoViricides pushes NV-387 to Phase II trials
NanoViricides (NYSE-A:NNVC) reported progress on its lead antiviral drug NV-387 and revealed plans to advance Phase II clinical trials for MPox and RSV. The Shelton, Connecticut-based company is waiting for results from its Phase I trial of NV-387 and has taken steps towards starting a Phase II trial of NV-387 for the treatment of MPox infection in Central Africa.
Neutral
Accesswire
1 month ago
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission (SEC) on Thursday, November 14, 2024. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057824001991/nnvc-20240930x10q.htm).
Neutral
Accesswire
2 months ago
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.
Charts implemented using Lightweight Charts™